Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

US Patent 6462091 · Granted Oct 8, 2002

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

PI-kinase inhibitors with anti-infective activity2024
ENPP1 inhibitors and their use for the treatment of cancer2023
ENPP1 inhibitors and their use for the treatment of cancer2023
Methods and compositions of localizing nucleic acids to arrays2023
Compounds and methods for treating oxalate-related diseases2022
4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA 2022
PI-kinase inhibitors with anti-infective activity2021
4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA 2021
Methods and compositions of localizing nucleic acids to arrays2021
Reversible covalent linkage of functional molecules2021
4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA 2020
Reversible covalent linkage of functional molecules2020